

GENERAL MEETING OF APRIL 30, 2021

WRITTEN QUESTIONS

Written questions may be submitted to the Company, pursuant to the rules established by law, with respect to any General Meeting. In conformity with the legislation in force, an answer is deemed to have been given to a written question provided it has been displayed on the Company's website.

On April 26, 2021 the Board received three questions from Mrs. Kelly HIRSCH, Member of Vancity Investment Management Ltd:

1st question:

“We have seen several positive steps by the pharmaceutical sector to expand manufacturing capacity, including cross-industry partnerships and voluntary licensing agreements (for example, your partnerships with BioNTech and JNJ). Yet, this does not seem enough to ensure fair and equitable access to COVID-19 tools across the world. What other steps are you considering to expand production and accelerate distribution of COVID-19 vaccine developed by other companies?”

Response to the written question:

“In addition to the two partnerships with BioNTech (for about 125 million doses) and J&J (>12 million doses per month), we just signed an agreement with Moderna (announced on April 26th), whereby Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna’s COVID-19 vaccine, starting in September 2021. This is another important step in the support to other manufacturers, in order to expand manufacturing capacity overall, and ensure access to COVID vaccines across the world.

We are also happy to see that other companies have decided to also engage in such unprecedented deals.”

2nd question:

“Sanofi continues to be involved in R&D against COVID-19, with the development of two COVID-19 vaccines (with GSK and Translate Bio respectively). Can you share more about the process used to plan for access during late stages of clinical development, and which access plans you have in place for these two vaccines (in addition to the statement of intent with Gavi for the vaccine co-developed with GSK)?”

Response to the written question:

“We are currently in Phase 2 with our COVID-19 vaccine candidates and are waiting for the results in order to be able to move to Phase 3.

As previously communicated, we intend to make our COVID-19 doses available globally.

Finally, we are working on our Phase 3 plan to ensure a broad level of diversity in our clinical recruitment to cover various possibilities (different age groups, different countries, different epidemiological situations), which will ease a broad access to our vaccines across the world.”

3rd question:

“Has Covid-19 changed your long term research agenda? If so, how are relatively underserved topics such as infectious diseases, medicine for children and access for LMICs taken into account?”

Response to the written question:

“The pandemic context led us to elevate our ambition for our Corporate Social Responsibility strategy. At the heart of our new social impact strategy is the creation of a non-profit, sustainable business unit focused on global health to increase the number of patients we can reach with our products. Building upon our large portfolio and global footprint, Sanofi Global Health will operate in 40 countries (among the lowest per capita GDP nations), and will improve how some of the most disadvantaged people in the world can access 30 of our most essential medicines, across various therapeutic areas including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. This unit will also help set up and foster sustainable care systems for those who need chronic treatment and complex care.

We also commit to donate 100,000 vials every year free of charge to support to patients with five different lysosomal storage disorders (LSDs), a group of rare genetic conditions caused by enzyme deficiencies.

We will also continue our efforts to fight polio and sleeping sickness, two of our historical programs that address global health issues. In December 2020, we announced we had renewed our five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people. In this context, we, the only pharmaceutical company that keeps developing and supplying treatments for African trypanosomiasis or sleeping sickness, have committed ourselves alongside the WHO to eliminate this neglected tropical disease in humans by 2030. For 40 years, we have supplied billions of polio vaccine doses, including hundreds of millions of donated doses to support the global polio eradication effort.

Finally, we are making a bold commitment to develop medicines for the most difficult to treat cancers in children, with the ambition to end childhood cancer. We will evaluate the prospects for pediatric indications in our vibrant pre-clinical oncology pipeline and we expect to build up new partnerships with regulators and advocacy and patient groups.”

* * *